Reframe Daily: Crohn’s patients improved with a “fasting-mimic” diet—plus a teen brain boost and a new TB drug

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible health research updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: A fasting-mimicking eating plan helped more people with Crohn’s disease feel better and reach remission, a teen interval-bike program improved attention on brain tests, a new antibody combo showed early promise for cancers that resisted immunotherapy, a trial found a pill improved “slow blood flow” heart-artery chest pain measures, and researchers reported a new TB drug that worked in animals and may be safer.

Good news: A special “fasting-mimicking” eating plan helped more people with Crohn’s disease feel better and reach remission, and it also lowered a gut inflammation marker.

A fasting-mimicking diet in patients with mild-to-moderate Crohn’s disease: a randomized controlled trial

Market readiness: 🙂🙂🙂🙂🙂 (It’s a dietary approach that can be done now with medical guidance; no new FDA product approval is required)

Good news: A 12-week bike interval program helped more teens with overweight/obesity improve attention and “thinking speed” on brain tests.

Individual response to continuous and interval training on cognitive and brain-derived neurotrophic factor in adolescents with overweight/obesity

Market readiness: 🙂🙂🙂🙂🙂 (Exercise programs are available now in the US; this study adds stronger evidence for how to structure them)

Good news: In a controlled trial for people with chest pain and “slow blood flow” in heart arteries, this medicine improved heart blood-flow measures and was tolerated.

Efficacy and safety of Shexiang Tongxin pill for coronary slow flow phenomenon: a multicenter, randomized, controlled phase IV trial

Market readiness: 🙂🙂🙂 (Tested in a phase IV study and used in some countries, but it’s not an FDA-approved US therapy)

Good news: A new antibody treatment looked manageable in an early trial and helped some patients whose cancers had stopped responding to prior immune therapy.

Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial

Market readiness: 🙂🙂 (Early human testing; more/larger trials are needed before it could be available in the US)

Good news: Scientists built a new TB drug that worked well in animal tests and looked less toxic than an older drug in the same class, which could mean safer TB treatment later.

Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis

Market readiness: 🙂 (Preclinical/animal-stage results reported here; not yet a US-available treatment)

Thank you for taking the time to take care of yourself and your loved ones.